Our Stocks to Watch today include Exit Only, Inc. (OTC: EXTO), eWorld Companies, Inc. (OTC: EWDI), Aethlon Medical, Inc. (OTCBB: AEMD), Aurelio Resource Corporation (OTCBB: AULO), Amarin Corporation plc (NASD: AMRN).
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts
EXIT ONLY (OTC: EXTO)
"Up 33.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EXTO.php
Exit Only Inc., which owns Text4Cars.com, is a leader in Pay-Per-Contact advertising through an Internet based community for new and used vehicles. The Company's web site contains a database through which sellers can sell their vehicles without paying a listing fee and buyers can search from thousands of sales offerings. Text4cars.com's unique system feature is in its Pay-Pr-Contact charge to the seller. A buyer searches the database of cars located on the Text4Cars.com website and finds a car they are interested in. The Buyer then sends a text message with contact information to the seller of the vehicle through SMS text messaging at a Pay-Per-Contact charge. This results in charges to the seller which only comes about in the event of firm leads from prospective buyers. Currently established in Canada, Text4cars is planning an expansion into US markets over the coming months.
EXTO News:
November 19 - Exit Only, Inc. Successfully Defends Trademarks
Exit Only, Inc. (OTC: EXTO), which owns Text4Cars.com, announced that it has successfully defended their trademarks in an out of court settlement.
Back in March, a Canadian company developed a site using the "text4" name as well as replicated the business model. Contact was made but no assistance from the Canadian company to settle was the conclusion. Exit Only, Inc. was left with no choice but to pursue litigation. After disputing for 2 months, a settlement was finally agreed upon. The settlement resulted in the shut down of the primary site, all related sites with the "text4" brand and the revocation of their existing trademark applications.
David Dion, CEO of Exit Only, comments, "We know that it was a matter of time before our platform and concept would be copied by competitors. The company has been proactive with how we've planned to protect our brand and business model. By pursuing trademark rights back in April, we have successfully defended our brand from the first copycat business. This will not be the only one that will come up, there will be others. This only reassures us that we have a built something worthy of copying, and only fuels our company's drive to push even harder to become one of the primary sites for online vehicle transactions. We have further mitigated protection to continue securing our brand for the future."
The award in the settlement not only confirms that the "text4" brand is protected but it secures all domain names and urls related to the trademarks. Having successfully defended the trademarks, this sets an example of how replicating Exit Only, Inc.'s business model will pose as a major obstacle for any competitor.
EWORLD COMPANIES NEW (OTC: EWDI)
"Up 20.00% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/EWDI.php
eWorldCompanies, Inc. operates as an online marketing and advertising technologies company that develops and markets technologies using media, flash, animation, and 3D graphics to help individuals and businesses market and advertise on the Internet. eWorld's patented Boomerang Media Station is a free software program that offers the user one-click access to various entertainment experiences and convenience benefits. Boomerang Media Station provides information related to sites offering news, sports and entertainment information, movies and television clips, and streaming video and/or music sites where users can get up-to-the-minute news feeds and access or download movies, music, games, or other proprietary media content. The company's other products and services include WALRUS system, which provides assistance as the user searches, surfs, or shops the net, suggesting relevant topics, products, and services based on user's browsing and searching habits; eWorldMail, a media email system that allows user to create 20-40 second TV-like email messages, broadcast them to various recipients, and track how many recipients open, watch, click-through, and respond to each message; eWorldSites, a browser-based tool that allows even a novice to create a flash Web site with point-and-click operation; and StayRelated.com, which enables the user to establish various online networks, where they can stay in touch with friends, family members, or any group of people they select. The company is based in Los Angeles, California.
EWDI News:
November 16 - eWorld Entertainment, Inc. is Sponsor and Exhibitor of 'Marbella Film Festival On Tour' in Miami, Florida on November 18
eWorld Entertainment, Inc., a wholly owned subsidiary of eWorld Companies, Inc. (OTC: EWDI), will be a sponsor and primary exhibitor at the "Marbella International Film Festival On Tour" in Miami, Florida on Sunday, November 18, 2007. This is the first in a series of one-day international exhibitions of the Marbella Film Festival that took place in Marbella, Spain on October 5, 6 & 7, 2007, in which eWorld Entertainment, Inc. was a main sponsor. Additional tour stops will take place in late 2007/early 2008 in London, Dublin, Berlin, Toronto, and Los Angeles.
The Marbella Film Festival is an annual event that offers an opportunity for independent international film makers to showcase their latest works to the international film community, and also provides a platform for upcoming directors and producers to showcase their talent. The Marbella Festival is truly international in scope and will include works from Europe, the Americas, Africa, Asia and the Middle East. In addition to film screenings, the festival will also include events include film premieres, music, dance, art exhibitions, workshops, lectures, fashion shows and gala evenings.
eWorld was featured at the main festival as a main sponsor, and also sponsored and presented one of the Festival's major awards. The Festival tour will feature a screening of the award winners at this year's show, and eWorld will also use the festival to introduce the international film community to its latest Internet technologies for downloading and watching live and archived television, movies and streaming video, and the unique ability of its Boomerang Media Station to deliver free and pay-per-view programming over the web.
AETHLON MEDICAL INC (OTCBB: AEMD)
"Up 20.75% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AEMD.php
Aethlon Medical is the developer of the Hemopurifier®, a first-in-class medical device to treat infectious disease. The Hemopurifier® addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. The Hemopurifier® is a single use extracorporeal device that converges hollow-fiber filtration technology with immobilized affinity agents to capture viruses and soluble glycoproteins from the blood. The device has been designed to mimic the natural immune response of clearing infectious viruses and immunosuppressive proteins from circulation. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier® are being conducted with researchers at the Government of India’s National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier® in a 24-treatment human study and is now conducting follow-on safety studies at the Fortis Hospital in Delhi, India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier® as a broad-spectrum treatment countermeasure against category “A” bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier® technology can be accessed online at www.aethlonmedical.com.
AEMD News:
November 19 - The Aethlon Hemopurifier(R) Reverses Immune Suppression in Cancer
Aethlon Medical, Inc. (OTCBB: AEMD), a pioneer in developing medical devices to treat infectious disease, announced that researchers have documented the Aethlon Hemopurifier® is able to remove the immunosuppressive activity normally found in the fluid of cancer patients. Aethlon recently discovered the Hemopurifier® efficiently captures tumor secreted exosomes that inhibit the ability of the immune system to combat cancer. In follow-on studies, led by Dr. Douglas Taylor at the University of Louisville, it has now been demonstrated that the capture of exosomes by the Hemopurifier® does result in reversing immunosuppressive activity. Dr. Taylor is a recognized authority on the causative effects of immune suppression in cancer patients. He is credited with the initial characterization of exosomes and is a leading peer reviewed author on the subject.
“Based on emerging data, we envision the Hemopurifier® will become a treatment standard that enhances the benefit of therapies administered to those who suffer from cancer,” stated James A. Joyce, Chairman and CEO of Aethlon Medical.
In the studies, the Aethlon Hemopurifier® completely removed the immunosuppressive activity normally found in the ascites fluid of ovarian cancer patients. Immunosuppressive activity in ovarian cancer patients is known to correlate with disease progression and long-term survival. The studies measured the expression of two biological markers required for T-cell activation. The markers, Jak-3 kinase and CD3-zeta chain expression are respectively required for interleukin (cytokine) activation of cell proliferation and T-cell receptor mediated activation. Both markers are highly expressed in T-cell lines. When cells were subjected to ovarian cancer ascites fluid, both markers were consistently absent. However, the circulation of the same ascites fluid through the Aethlon Hemopurifier®, allowed the expression of both biological markers necessary to activate the immune response. Further details of the study will be published in an upcoming report.
“We have significantly increased our market opportunity as studies validate the application of the Hemopurifier® beyond infectious disease,” concluded Joyce. The annual size of the cancer treatment market exceeds $43 billion.
Previously, Dr. Taylor documented that 60% of circulating exosomes were removed from the blood of ovarian cancer patients during first pass (approximately 10-minutes) through a small scale Hemopurifier®. The capture data was consistent over the course of five different studies. Exosomes, are released by solid tumors, lymphomas, and leukemia. They induce T-cell apoptosis (programmed cell death), and block T-cell signaling, proliferation, and cytokine production. High concentrations of circulating exosomes correlate with reduced T-cell production and tumor progression in cancer patients. The ability to reduce the presence of circulating exosomes would reverse immune suppression and increase patient responsiveness to both immunotherapy and chemotherapy. As such, Aethlon believes the Hemopurifier® can address a significant unmet medical need in cancer care. Aethlon further disclosed that Dr. Taylor has not received nor requested any compensation for conducting these research studies.
AURELIO RESOURCE CORPORATION (OTCBB: AULO)
"Up 29.03% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AULO.php
Aurelio Resource Corporation is a mineral exploration and development company focused on achieving mid-tier producer status. The Company's wholly-owned Hill Copper-Zinc Project, Arizona contains a number of potentially low-cost, bulk-tonnage, open-pit-mineable deposits close to surface containing significant amounts of copper, zinc, silver and gold. The Company recently announced an independent estimate of the mineralized material at the MAN Area of the Project totaling 63.8 million tons at an average grade of 0.56% copper-equivalent. Aurelio has also acquired the rights to explore, and an option to purchase, the Gavilanes gold porphyry deposit in Durango, Mexico.
AULO News:
November 16 - Aurelio Intercepts 165 feet Averaging 2.30% Zinc and 18.25 ppm Silver at Hill Copper-Zinc Project, Arizona
Aurelio Resource Corporation (OTCBB: AULO) (FWB: F3RA) announced further results from recent infill drilling in the MAN Area of the Company's wholly owned Hill Copper-Zinc Project, located in the Turquoise Mining District, Cochise County, Arizona.
The grades in drill hole BR07-27 are significantly higher than the average grades reported in the CAM mineralized material inventory (see Aurelio’s October 30, 2007 news release). The latest results exceed the grades reported from surrounding holes drilled in the late 1980s by Santa Fe Pacific Mining, Inc.
AMARIN CORPORATION PLC AD (NASD: AMRN)
"Up 14.19% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AMRN.php
Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes Miraxion for Huntington's disease, two programs in Parkinson's disease, one in epilepsy and one in memory and cognition. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has a proprietary lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain that can be leveraged in a wide range of disease applications for its own product pipeline or with potential partners. Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively. For press releases and other corporate information, visit www.amarincorp.com.
AMRN News:
November 19 - Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program
Amarin Corporation plc (NASD: AMRN; "Amarin" or "Company") announced that management has met with the U.S. Food and Drug Administration (FDA) following the completion of a comprehensive data review from its large-scale Phase III studies of Miraxion to treat Huntington's disease (HD). The FDA indicated that one additional Phase III trial demonstrating robust results, in conjunction with the confirmatory evidence from the existing clinical data, may be sufficient clinical data to support a New Drug Application.
Rick Stewart, Chief Executive Officer of Amarin, commented "We are pleased with the results of the comprehensive clinical data review and are encouraged by the outcome of our recent dialogue with the FDA. We are now in discussions with the Huntington Study Group to determine the optimal design of such a single Phase III trial. We are also considering whether Amarin will conduct this study itself or seek a collaborative partner with which to advance Miraxion in Huntington's disease."
Since the most recent update on Miraxion to treat HD on August 1, 2007, the Company has continued a comprehensive analysis of all clinical data with its advisors. This additional analysis supports the preliminary findings, suggesting a clinical benefit from a longer treatment period for Miraxion.
Positive 12-month results from U.S. Phase III Trial (TREND-HD)
The TREND-HD trial, conducted by the Huntington Study Group in the U.S. and Canada in 316 patients, was a 6-month, double-blind placebo controlled study followed by a further 6-month extension period where all patients received 2 grams per day of Miraxion. The primary endpoint was the 6-month change in TMS-4, a scale that measures motor symptoms. As previously announced on April 24, 2007, at the 6-month time point, there was no statistically significant difference in efficacy between the Miraxion group and the placebo group.
Analysis of the 12-month data showed a statistically significant difference in TMS-4 between the long term Miraxion group (12-months treatment) and those patients who had switched to Miraxion at 6-months. Treatment codes were not broken at the switching point so investigators and patients remained blinded to receipt of Miraxion or placebo in the initial 6- month period. These results suggest that there is benefit from a longer treatment period with Miraxion and are consistent with the 24-month open-label data from the earlier 135-patient trial completed in 2003.
Positive Additional Analysis
A longitudinal analysis, which is a widely accepted and validated alternative statistical methodology, was applied to all available clinical data as part of the comprehensive review.
TREND-HD Trial Outcome
The longitudinal methodology was applied to both the 3 and 6-month combined results as well as the 3, 6, 9 and 12-month combined results. A statistically significant difference between the Miraxion and placebo groups was identified in each of the 3-6 month and the 3, 6, 9 and 12-month analyses.
Earlier 135 patient Trial Outcome
In the earlier 135-patient study, the longitudinal analysis showed a statistically significant difference between Miraxion and placebo in the per protocol patient groups and, additionally, a greater degree of statistical significance in the intent to treat genetic sub-group of patients with a CAG(less than or equal to)44 than in the previous analysis.
Analysis was also conducted on the 24-month open label data from the 135-patient trial, in which patients initially randomized to treatment with placebo had been switched to Miraxion and treated for 12 months. After switching to Miraxion, these patients demonstrated an effect of similar magnitude to patients randomized to treatment with Miraxion at baseline.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
